EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY 4.0

JYP0322, a highly selective and brain-penetrant ROS1 inhibitor, overcomes ROS1G2032R resistance mutation in NSCLC: The first-in-human phase 1 trial

Yuxiang Ma, Jinhui Xue, Fangfang Gao, Yunpeng Yang, Yuanyuan Zhao, Linlin Wang, Zhangzhou Huang, Chunjiao Wu, Yongzhong Luo, Juan Li, Jian Fang, Zhengbo Song und 22 weitere

Cancer Cell · 2026

DOI: 10.1016/j.ccell.2026.03.018 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Cancer Cell, 2026. Verfasst von Yuxiang Ma und 33 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guan…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Brain, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sun Yat-sen University Cancer Center, Guangzhou Municipal Science and Technology Bureau, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targeted therapies against ROS1-rearrangements face limitations due to resistance mutations, brain metastases, and central nervous system toxicities. We have developed a next-generation, brain-penetrant ROS1 inhibitor, JYP0322, that can overcome resistance mutations (e.g., ROS1G2032R) while minimizing off-target inhibition. In preclinical studies, JYP0322 demonstrated >130-fold selectivity over TRKA, potent antitumor activity in ROS1 re-arrangement and ROS1G2032R tumor models, and effective brain penetration (CSF/plasma AUC ratio 0.893). In a phase I trial (NCT06128148) enrolling 89 non-small cell lung cancer (NSCLC) patients with ROS1-fusion (36% with brain metastases), JYP0322 was well tolerated with low TRK-related neurologic events (dizziness: 6.7%; headache: 3.4%). Among 80 efficacy-evaluable patients, the objective response rate (ORR) was 95.7% in TKI-naive, 57.1% in those with ≥2 prior TKIs, and 77.8% in ROS1G2032R-mutant patients. Intracranial ORR was 55.6% among brain-metastatic patients. These findings highlight JYP0322 as a promising therapy for heavily pretreated NSCLC patients, including those with brain metastases or ROS1G2032R mutations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsBrainBrain NeoplasmsCarcinoma, Non-Small-Cell LungDrug Resistance, NeoplasmLung NeoplasmsProto-Oncogene ProteinsAdultAgedAnimalsFemaleHumansMaleMiddle AgedCell Line, TumorMutationProtein-Tyrosine KinasesReceptor, trkATyrosine Kinase InhibitorsXenograft Model Antitumor Assays

Stichwörter der Autor:innen

G2032R mutationROS1 inhibitorbrain metastasesphase 1 trialtyrosine kinase inhibitor

Substanzen

Antineoplastic AgentsProtein-Tyrosine KinasesProto-Oncogene ProteinsReceptor, trkAROS1 protein, humanTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
  • Department of Internal Medicine, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou 450008, China.
  • Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250117, China.
  • Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou 350014, China.
  • Jilin Cancer Hospital, Jilin 130051, China.
  • The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410031, China.

Förderung

  • Sun Yat-sen University Cancer Center
  • Guangzhou Municipal Science and Technology Bureau
  • National Natural Science Foundation of China

Zitieren

APA

Ma, Y., Xue, J., Gao, F., Yang, Y., Zhao, Y., Wang, L., Huang, Z., Wu, C., Luo, Y., Li, J., Fang, J., Song, Z., Li, Y., Ma, H., Guo, Q., Yi, T., Liu, X., Liu, Z., Zhou, J., …, & Zhao, H. (2026). JYP0322, a highly selective and brain-penetrant ROS1 inhibitor, overcomes ROS1G2032R resistance mutation in NSCLC: The first-in-human phase 1 trial. Cancer Cell. https://doi.org/10.1016/j.ccell.2026.03.018

Vancouver

Ma Y, Xue J, Gao F, Yang Y, Zhao Y, Wang L, et al. JYP0322, a highly selective and brain-penetrant ROS1 inhibitor, overcomes ROS1G2032R resistance mutation in NSCLC: The first-in-human phase 1 trial. Cancer Cell. 2026. doi:10.1016/j.ccell.2026.03.018

BibTeX
@article{Ma2026,
  author = {Ma, Yuxiang and Xue, Jinhui and Gao, Fangfang and Yang, Yunpeng and Zhao, Yuanyuan and Wang, Linlin and Huang, Zhangzhou and Wu, Chunjiao and Luo, Yongzhong and Li, Juan and Fang, Jian and Song, Zhengbo and Li, Yongsheng and Ma, Huiwen and Guo, Qinxiang and Yi, Tienan and Liu, Xiting and Liu, Zhihua and Zhou, Jianya and Dong, Xiaorong and Yu, Qitao and He, Jianbo and Yang, Liuzhong and Fang, Wenfeng and Sun, Yuping and Qi, Yaling and Lv, Jing and Ge, Zhen and Xia, Binyan and Li, Lei and Wang, Wei and Huang, Yan and Zhang, Li and Zhao, Hongyun},
  title = {JYP0322, a highly selective and brain-penetrant ROS1 inhibitor, overcomes ROS1G2032R resistance mutation in NSCLC: The first-in-human phase 1 trial},
  journal = {Cancer Cell},
  year = {2026},
  doi = {10.1016/j.ccell.2026.03.018}
}
Kostenlos starten →